

Review

Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease

Er-jin Wang¹, Ming-Yue Wu², Zheng-yu Ren¹, Ying Zheng¹,
Richard D. Ye³, Chris Soon Heng TAN⁴, Yitao Wang¹ and
Jia-Hong Lu^{1,5,*}

¹State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China, ²Center for Metabolic Liver Diseases and Center for Cholestatic Liver Diseases, Department of Gastroenterology, The First Affiliated Hospital (Southwest Hospital), Third Military Medical University (Army Medical University), Chongqing, 400038, China, ³Kobilka Institute of Innovative Drug Discovery, School of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen, 518172, China, ⁴Department of Chemistry, College of Science, Southern University of Science and Technology, Shenzhen, 518055, China and ⁵Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, University of Macau, China

*Correspondence. Email: jiahonglu@um.edu.mo

Received 16 November 2022; Revised 22 December 2022; Accepted 16 January 2023

Abstract

Inflammatory bowel disease (IBD) is a chronic, non-specific, recurrent inflammatory disease, majorly affecting the gastrointestinal tract. Due to its unclear pathogenesis, the current therapeutic strategy for IBD is focused on symptoms alleviation. Autophagy is a lysosome-mediated catabolic process for maintaining cellular homeostasis. Genome-wide association studies and subsequent functional studies have highlighted the critical role of autophagy in IBD via a number of mechanisms, including modulating macrophage function. Macrophages are the gatekeepers of intestinal immune homeostasis, especially involved in regulating inflammation remission and tissue repair. Interestingly, many autophagic proteins and IBD-related genes have been revealed to regulate macrophage function, suggesting that macrophage autophagy is a potentially important process implicated in IBD regulation. Here, we have summarized current understanding of macrophage autophagy function in pathogen and apoptotic cell clearance, inflammation remission and tissue repair regulation in IBD, and discuss how this knowledge can be used as a strategy for IBD treatment.

Key words: Autophagy, Inflammatory bowel diseases, Inflammation, Tissue repair, Efferocytosis, Macrophage

Highlights

- Mutations in autophagy-related genes are associated with increased risk of IBD.
- Induced autophagy of intestinal macrophages is of great significance in enhancing the clearance of apoptotic cells, promoting inflammation resolution and tissue repair.
- Targeted and controllable regulation of macrophage autophagy at the site of intestinal inflammation is a potential strategy for the treatment of IBD in the future.

Background

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract with unknown etiology that has been divided into Crohn's disease (CD) and ulcerative colitis (UC) [1]. Clinically, IBD patients usually have symptoms of diarrhea, abdominal pain, blood in the stool and weight loss. In the past decade, the incidence of IBD has shown a rapid upward trend, especially in developed countries [2,3]. To date, the pathogenesis of IBD has been associated with different factors, such as genetic susceptibility, environmental stimulation, intestinal flora triggering and immune dysfunction. It is generally believed that an abnormal immune system and an inflammatory response in the intestinal system play important roles in the occurrence and development of IBD [4,5]. In addition, some environmental, genetic and infectious factors, as well as disturbances of the gut microbiota homeostasis, may be factors that contribute to the persistence of the pathological state [6–11].

Autophagy, a conserved process in eukaryotic evolution, is an important pathway for cells to degrade damaged organelles, folded proteins and other substances through lysosomes. It is divided into microautophagy, macroautophagy and chaperone-mediated autophagy. Macroautophagy is the most widely studied type of autophagy. Unless otherwise mentioned, all autophagy described in this review is macroautophagy. Autophagy occurs throughout the life of cells and can be further induced by conditions such as starvation and inflammation. The process of autophagy generally includes initiation (the formation of double-membrane autophagosomes), elongation, maturation (the binding of autophagosomes and lysosomes) and cargo degradation. Accumulating studies have confirmed that autophagy is closely related to the occurrence and regulation of inflammatory diseases including IBD [12]. Autophagic genes, such as ATG16L1, ATG4, ULK1, nucleotide-binding oligomerization domain 2 (NOD2) and nuclear receptor binding factor 2 (NRBF2), have all been involved in IBD regulation; in particular, ATG16L1 and NOD2 mutations were identified to be causative of IBD in a genome-wide association study (GWAS) of IBD [13,14]. These autophagy genes were reported to regulate the function of goblet cells, increase defense ability and regulate inflammatory responses [15]. However, the principal way in which autophagy is involved in the regulation of IBD progression is still not clear.

As a canonical type of important immune cell, macrophages play an irreplaceable role in maintaining intestinal homeostasis. Polarization into the pro-inflammatory M1 subtype and the anti-inflammatory M2 subtype as the important regulatory manner of macrophage function has been intensively studied [16]. In healthy individuals, the intestinal system is protected from pathogenic microorganisms by a thick mucus layer, the tight epithelial cell barrier, and supervision of immune cells, especially macrophages, in the lamina propria [17–19]. These macrophages exhibit a highly phagocytic and anti-inflammatory phenotype [20] to clear cellular debris, dead cells, infected cells and harmless

bacteria in an immune-silencing manner [21]. However, when the intestinal barrier or the pathogen-clearance pathway is destroyed, intestinal macrophages will be differentiated into an M2-like pro-inflammatory state, secrete abundant inflammatory cytokines and initiate a comprehensive immune response. Continuing exposure to microbial antigens and the uncontrolled immune response can cause further mucosal damage, altered junctional function and structure between epithelial cells, and lead to the accumulation of a large number of apoptotic cells to trigger a vicious cycle of inflammation aggravation. Therefore, enhancing the phagocytic function of macrophages to promote the clearance of pathogens and apoptotic cells is significant for inflammation alleviation and tissue repair in IBD.

The process by which phagocytic cells (mainly tissue-resident macrophages and dendritic cells) engulf dead or apoptotic cells is defined as 'efferocytosis'. Previously, we found that NRBF2-deficient macrophages displayed impaired efferocytosis ability, which increased the susceptibility of mice to dextran sulfate sodium salt (DSS)-induced colitis [13]. In addition, many other reports have identified the critical roles of autophagic genes involved in macrophage function regulation in IBD (Table 1). These studies suggest that autophagic function in macrophages is a crucial factor in the regulation of IBD progression.

Therefore, in-depth exploration of the mechanisms of autophagy and macrophage activation in inflammation alleviation and tissue repair is beneficial to the treatment of IBD. This review discusses therapeutic strategies for promoting clearance of pathogens and apoptotic cells, tissue inflammation resolution and tissue repair by regulating autophagy in macrophages (Figure 1).

Review

Autophagy in IBD

There is substantial evidence linking abnormal autophagy to IBD. Autophagy-related protein Beclin-1 levels and LC3-II/I ratios in intestinal biopsy samples from IBD patients are higher than those in healthy controls and are positively correlated with disease severity [22], indicating the correlation between autophagy levels and IBD. In animals, mice with myeloid cell-specific deletion of autophagy initiation protein Atg7 are more susceptible to experimental colitis, with increased colonic cytokine expression and systemic bacterial invasion [23]. Deficiency of the autophagy gene class III PI3-kinase (*PIK3C3*) or *NRBF2* leads to IBD-like damage and pro-inflammatory responses under sterile conditions in zebrafish and mice [13,24].

To date, >150 loci have been identified to be associated with IBD based on single-nucleotide polymorphism frequency analysis in subjects with IBD vs. controls [12,25,26], including ATG16L1, immunity-related GTPase family M protein (*IRGM*), NOD2 and some other autophagy-related genes [27–29]. ATG16L1 is the earliest identified and most studied autophagy-related gene associated with IBD [14]. During the early stages of autophagosome maturation, ATG16L1

Table 1. Effects of autophagy-related gene mutations in macrophages on IBD

Gene	Mutation site	Model	Mechanisms in macrophages	References
ATG16L1	T300A	IBD patients	Influence the polarization of macrophages towards the M2 subtype; does not significantly affect NOD2 function in monocytes	[14] [39] [40]
	T300A	Atg16l1 ^{flf} or colitis model mice	Enhance polyubiquitination of TRAF6 or RIPK2; induce TLR-, NLR- or IFN- β (TRIF)-mediated inflammatory signaling; impair mitophagy and MHC class II Ags processing; alter intracellular trafficking to the lysosomal compartment	[41] [42] [43]
	T316A	IBD patients	Defective clearance of the ileal pathogen <i>Yersinia enterocolitica</i> and an elevated inflammatory cytokine response	[31]
IRGM	Mutation	IBD patients	Affect autophagy resulting in inability to mediate adherent-invasive <i>E. coli</i> replication	[32,44]
NOD2	Frameshift or missense variants	IBD patients	Alter the recognition of microbial pathogens components and/or by over-activating NF- κ B	[28]
		IBD patients	Affects the activation of nuclear factor NF- κ B	[29]
NPC1	Mutation	IBD patients	Defective NOD2–RIPK2–XIAP pathway affects autophagosome maturation, resulting in poor elimination of intracellular bacteria	[45]
GPR65	I231L	<i>Citrobacter rodentium</i> -induced mice	Impair clearance of intracellular bacteria and accumulation of aberrant lysosomes	[36]
RNF186	rs6426833 and A64T	IBD patients	Impair E3-ubiquitin ligase activity resulting in poor clearance of intracellular bacteria	[38]
ULK-1	Mutation	IBD patients	Affect autophagy resulting in inability to mediate Adherent-Invasive <i>E. coli</i> replication	[44]
NRBF2	Deficiency	DSS-induced mice	Affect phagosome–lysosome fusion in macrophages	[13]
OPTN	rs12415716	IBD patients	Influence the release of TNF and IFN- γ	[46]
MTMR3	Deficiency	Citrobacter colitis mice	Influence the release of pro-inflammatory factors	[47]
	rs713875	IBD patients	Increase MTMR3 expression, decrease PtdIns3P and autophagy, increase caspase-1 activation	[48]
ATG5	Knocked down or knocked out	THP-1, iBMM and RAW264.7 cell lines	Cause more MIF secretion, affect the regulation of mitochondrial ROS	[49]
Atp6v0d2	Knocked out	DSS or salmonella-induced mice	Increase mitochondrial damage, enhance inflammasome activation and decrease <i>Salmonella typhimurium</i> clearance	[50]

ATG autophagy-related genes, IBD inflammatory bowel disease, NOD2 nucleotide-binding oligomerization domain 2, TLRs toll-like receptors, NLRs NOD-like receptors, IFN interferon, MHC major histocompatibility complex, IRGM immunity-related GTPase family M, NF- κ B Nuclear factor kappa-light-chain-enhancer of activated B cells, NPC Niemann-Pick type C, RIPK2 receptor interacting protein kinases 2, XIAP X-linked inhibitor of apoptosis protein, GPR65 G protein-coupled receptor 65, RNF186 ring finger protein 186, ULK-1 Unc-51 like autophagy activating kinase 1, NRBF2 nuclear receptor binding factor 2, OPTN optineurin, MTMR3 myotubulin-related protein 3, DSS dextran sulfate sodium salt, MIF macrophage migration inhibitory factor

acts as an adaptor that stabilizes the interaction between the ubiquitin-like protein ATG12 and the E3 ubiquitin ligase-like protein ATG5, forming the ‘ATG16L complex’ with lipidated ATG8 (also known as LC3 in mammals) in an E3 ligase-like manner, which is required for autophagosome membrane elongation [30]. The T300A mutant of ATG16L1 leads to defective intestinal pathogen clearance and elevated inflammatory cytokines by reducing autophagy [31]. GWAS confirmed the association of IRGM with CD [32,33]. In humans, IRGM is a 20 kDa protein consisting of 181 amino acids expressed in the large intestine, small intestine and lymphocytes, and is involved in bacterial killing, vacuolar trafficking, lysosome acidification, phagosome maturation and virus-induced autophagy. It is also known to be involved

in the control of intracellular *Mycobacterium tuberculosis* proliferation through autophagy in macrophages [34]. In addition, Saxena *et al.* [35] showed that the loss of NOD2 leads to the impairment of mitochondrial ATP synthesis and thus damages the epithelial barrier function. Lassen *et al.* [36] identified the roles of nine IBD susceptibility loci in autophagy through genomic screening, and characterized the role of GPR65 in maintaining lysosomal function and thus affecting clearance capacity and lysosome accumulation in epithelial cells and macrophages. The IBD-related gene ring finger protein 186 (RNF186) has been shown to maintain intestinal homeostasis through autophagy [37,38]. These studies demonstrate the importance of autophagy in the regulation of IBD.




Figure 1. Strategies to enhance macrophage autophagy for the treatment of IBD. Macrophage autophagy at sites of inflammation in IBD can promote pathogen and apoptotic cell clearance, inflammation resolution and tissue repair. Firstly, macrophage autophagy promotes the recognition and phagocytosis of pathogens mediated by TLR, NLR and other macrophage surface receptors. Secondly, in addition to inhibiting the inflammatory response mediated by the NF- κ B pathway, autophagy-related genes, such as ATG16L1, IRGM, GPR65, NPC1 and RNF186, are also involved in pathogen-containing phagosomes binding to lysosomes and degradation. Thirdly, Nrbf2 activates MON1-CCZ1-Rab7 to promote efferocytosis which induces the differentiation of macrophages into the anti-inflammatory M2 subtype. Fourthly, autophagy-activated macrophages secrete Wnt1, which promotes the repair of damaged epithelial barriers. Lyso lysosome, MDP muramyl dipeptide, AC apoptotic cells, TLR toll-like receptors, NLR NOD-like receptors, ROS reactive oxygen species, NPC Niemann-Pick type C

At the disease level, the relationship between autophagy and IBD has been well reviewed. In short, autophagy is mainly involved in the pathogenesis and progression of IBD through enhancing xenophagy to inhibit pathogenic infection, maintaining the intestinal barrier, promoting T cell activity and proliferation, and increasing intestinal macrophage activity and inflammatory signaling pathways. Regulating the autophagy level has the potential to intervene in the IBD process from multiple aspects, such as cell function and inflammation regulation. Given the important roles of macrophages in IBD, regulating intestinal macrophage autophagy will be an important strategy for IBD treatment. Details on how macrophage autophagy affects inflammation resolution and tissue repair in IBD will be elaborated later in this review.

Intestinal macrophages in IBD inflammation resolution and the tissue repair process

The gut is the organ in the body with direct contact with the outside. The intestinal epithelium separates the luminal contents from the body's immune system and is an important defense barrier to protect the homeostasis of the intestinal environment and reduce inflammatory responses [51].

The intestinal immune system is mainly composed of three mucosal barrier layers, namely, the superficial mucous layer, the epithelial cell layer and the submucosa immune cell layer. The mucous layer covers the mucosal surface and insulates the epithelium from direct contact with the luminal contents by means of a gel containing various proteases. The epithelial cell layer mainly includes intestinal epithelial cells, goblet cells, Paneth cells and enteroendocrine cells that are mainly responsible for absorbing nutrients and secreting some functional proteins. The submucosa immune cell layer is composed of a variety of immune and inflammation-related cells, including macrophages, neutrophils, eosinophils and lymphocytes [52], among which macrophages are the most studied.

It is generally believed that tissue-resident macrophages in the gut originate from the monocyte system in the bone marrow [53]. Intestinal tissue has the largest population of macrophages in the body. Under physiological conditions, intestinal macrophages maintain the homeostasis of intestinal epithelial cell numbers and tissue homeostasis by phagocytosing the continuously generated naturally apoptotic epithelial cells [54,55]. Depletion of macrophages results in increased susceptibility of mice to DSS-induced colitis

[56], indicating that macrophages are essential for maintaining mucosal homeostasis and protecting the body from pathogenic microorganisms *in vitro* and *in vivo* [57,58]. During inflammation, the two phenotypes of macrophages, M1 and M2, are continuously inter-switched, and an imbalance in this switch is thought to be important in the development of inflammation in IBD [59,60]. It is generally believed that at the beginning of inflammation, the number of M1 macrophages increases and that they secrete a large amount of pro-inflammatory factors such as reactive oxygen species (ROS), nitric oxide (NO), tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), IL-12 and IL-23. The secretion of IL-12 and IL-23 promotes the secretion of interferon- γ by macrophages and the recruitment of neutrophils to inflammatory sites for the purpose of inducing immunity and clearing pathogens [61]. However, sustained overexpression of M1-type responses eventually leads to destruction of the intestinal intrinsic barrier, intestinal epithelial cell apoptosis and granulation tissue hyperplasia. Furthermore, inhibition of M2 polarization leads to exacerbation of enteritis [60]. Conversely, upregulation of the expression profile of anti-inflammatory genes such as IL-4, IL-10 and TGF- β prevents excessive inflammation and promotes tissue recovery [62]. Therefore, promoting the differentiation of macrophages to the M2 anti-inflammatory phenotype is considered to be an effective approach for the treatment of IBD [63].

When suffering from invasion by endogenous or exogenous pathogens, macrophages receive 'eat-me' signals mainly through pattern recognition receptors (PRRs) [64], and induce adaptive immune responses by phagocytosing and presenting invading antigens to other immune cells [65]. When excessive stimuli lead to an imbalance of immune and inflammatory regulation, a large number of apoptotic cells will be observed. These apoptotic cells release 'find-me' and 'eat-me' signaling molecules, including ATP and phosphatidylserine, to recruit pro-inflammatory monocytes and macrophages to infiltrate inflamed tissues and participate in inflammation alleviation and tissue repair [66]. Insufficient clearance of apoptotic cells exacerbated the inflammatory response in a DSS-induced IBD mouse model [45], resulting in failure of tissue repair [67], whereas enhanced clearance of apoptotic cells can alleviate inflammation [68]. These results indicate that promoting the clearance of pathogens and apoptotic cells by macrophages and regulating the abnormal inflammation and immune response mediated by intestinal macrophages are important strategies for the treatment of IBD.

The uptake of apoptotic cells by macrophages (a process known as efferocytosis) is not only critical for improving the gut environment but is also an important event in phenotypic differentiation of macrophages. After recognizing and phagocytosing apoptotic cells, macrophages polarize towards the M2 phenotype, manifested by decreased expression of pro-inflammatory factors and chemokines [54,69] and increased expression of phagocytic receptors such as CD36 for further phagocytosis potential [70]. On

the other hand, M2 macrophages infiltrating inflammation sites secrete signaling molecules such as soluble growth factors, polyamines and Wnt glycoproteins [71,72], which play a role in maintaining intestinal homeostasis, inhibiting inflammation and promoting tissue regeneration by acting on epithelial cells [73–76]. Ortiz-Masiá *et al.* [77] detected increased expression of Wnt1 at both the protein and mRNA levels in intestinal macrophages from IBD patients. They found that macrophages in the lamina propria express Wnt1 and the proportion of cells expressing the ligand in damaged mucosa was higher than that in normal tissue. These results indicate that polarization of macrophages to the M2 type and phagocytosis of apoptotic cells are two processes of reinforcement. During these processes, macrophages secrete a large number of cytokines, which are beneficial to inflammation regression and wound repair in IBD.

Autophagy regulates macrophage function to promote inflammation resolution and tissue repair

Autophagy promotes recognition and clearance of pathogens

As mentioned earlier, macrophages need to deal with the dysfunction of inflammation resolution and fight against a large number of engulfed proteins, lipids and other degradation products under the conditions of IBD. This process has a large energy requirement. Phagocytosis and autophagy are two different modes for cells to obtain energy under nutrient-rich and nutrient-deficient conditions respectively, but they also share some pathways of material degradation to a certain extent. It is generally believed that macrophages, when subjected to pathogen invasion, enhance phagocytosis and clearance of pathogens by activating autophagy, thus freeing up more space for sustainable phagocytosis and regulating immune responses in the process.

The identification of pathogens by macrophage is mainly mediated by PRRs, such as NOD-like receptors (NLRs) in the cytoplasm and Toll-like receptors (TLRs) on the cell membrane surface, which are activated by their pathogen-associated molecular patterns [78]. NLRs and TLRs in macrophages and other innate immune cells have been shown to be closely related to autophagy, which is highly correlated with the mediation of innate immune responses in the gut [28,29]. The effect of the ATG16L1 T300A polymorphism on the TLR- or NLR-mediated signaling pathway in macrophages may be a major contributor to inflammation in CD [41]. Studies have shown that muramyl dipeptide, a component of bacterial peptidoglycan, activates NOD2 and recruits ATG16L1 to the bacterial entry sites on the plasma membrane to promote autophagy, which subsequently sequesters and kills invading *Streptococcus flexneri* and *Listeria* in autophagosomes [39,79,80]. Furthermore, macrophages with CD-associated Nod2 variants are unable to induce autophagy and had impaired ability to kill pathogenic bacteria [81]. The above results indicate that PRR achieves the regulation of autophagy in macrophages by interacting with Atg16l1. In addition, some molecules of selective autophagy were identified to be involved in selective

degradation of invaders [82]. For example, the adaptor proteins p62 and NDP52 promote selective recognition and autophagy in cytoplasmic bacteria such as *Salmonella typhimurium* [83,84]. All of the above findings suggest that bacteria-induced macrophage autophagy contributes to killing invasive bacteria, and these findings are further supported by the fact that macrophage autophagy deficiency results in failure of bacterial clearance.

Autophagy is essential for macrophages to maintain their function of dealing with exogenous pathogens. Adherent-invasive *Escherichia coli* (AIEC) is a pathogenic group of bacteria isolated from the ileum of CD patients [85,86]. To date, numerous studies have revealed the active role of intestinal macrophage autophagy in maintaining recognition and responding to AIEC invasion and damage [44,87,88]. In the intestinal lamina propria, AIECs are taken up by macrophages and then survive and proliferate within macrophage vacuoles [89]. When autophagy is defective, AIECs are more likely to escape from macrophages and proliferate rapidly [44,80,88,90,91]. A study in CD patients showed that cells deficient in the autophagy-related genes IRGM and ATG16L1 increased AIEC replication [80]. Pathogen-containing vesicles were reduced in primary Atg16L1-deficient mice macrophages and ATG16L1 T300A variant human macrophages, resulting in impaired bacterial clearance and reduced major histocompatibility complex (MHC) class II antigen processing [43]. Mice deficient in Atg16L1 in bone marrow cells have increased numbers of IgA-coated gut bacteria [43]. A study by Sun *et al.* [92] identified a key role of IL-23 in promoting the clearance of bacteria by macrophages, and the performance of this function was partly related to the induction of ATG16L1 expression and autophagy.

Mechanisms of intracellular bacterial clearance barriers may be related to phagosome maturation barriers. Schwerd *et al.* [45] studied patients with NPC1-mutated Niemann-Pick type C and early-onset CD-like intestinal inflammation, showing that NOD2-RIPK2-XIAP pathway-induced antibacterial autophagy deficiency is the key cause of granulomatous intestinal inflammation, and this deficiency interferes with NOD-dependent xenophagy. Under such conditions, autophagosome maturation dysfunction, but not lysosomal dysfunction, affects autophagic elimination of intracellular bacteria, leading to dysregulated cytokine responses. Autophagy-inducing drugs can restore bacterial killing. Lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, activates TLR4 and other TLRs, thereby reducing Bcl-2 binding to Beclin 1 and increasing autophagy in macrophages [93,94]. In response to intracellular pathogens, Caspase 4 is activated, leading to inflammasome activation, which positively regulates autophagosome biogenesis and trafficking to lysosomes in macrophages, and increases efferocytosis-mediated pathogen elimination [95].

Taken together, pathogen invasion induces autophagy in macrophages. However, promoting pathogen elimination

may also involve the activation of inflammatory signaling pathways. This is worth noting since it is expected to reduce pathogens and inflammation in IBD at the same time. In addition, more mechanistic studies are needed to elucidate the interplay of autophagy and inflammasome activation under different pathogen invasion conditions.

Autophagy promotes phagocytosis of apoptotic cells by macrophages In recent years, efferocytosis has gradually attracted attention. When intestinal inflammation occurs, the differentiation of monocytes into mature macrophages is impaired, and the accumulation of apoptotic cells or abnormal efferocytosis causes IBD to progress to a severe degree [96,97]. Promoting efferocytosis is beneficial for the treatment of IBD. Efferocytosis directly removes apoptotic and dying cells that release inflammatory mediators, promoting the transition of macrophages to the M2 subtype [98]. Numerous studies have demonstrated the critical role of efferocytosis in atherosclerosis, cancer and various inflammatory diseases [99–101]. Mice lacking efferocytosis have accumulation of apoptotic bodies in tissues and phagocytes. A study using two different IBD mouse models confirmed that pro-catabolic factors released by efferocytic macrophages can effectively reduce intestinal inflammation and promote mucosal healing [102].

Autophagy is closely related to efferocytosis. Efferocytosis, including LC3-associated efferocytosis, shares multiple regulators with canonical autophagy, especially fusion and degradation with lysosomes [103]. Multiple studies on atherosclerosis have shown that enhancement of autophagy can induce efferocytosis of macrophages [104,105], while the absence of autophagy leads to a decrease in aortic efferocytosis [106]. Our recent study found that autophagy-related gene NRBF2-deficient mice were more susceptible to DSS-induced colitis, exhibiting more pronounced intestinal inflammation and apoptotic cell aggregation. This is due to damage of the mechanism by which NRBF2 activates the MON1-CCZ1-Rab7 module to promote the fusion of apoptotic cell-containing phagosomes and lysosomes within macrophages [13]. Until now, studies targeting the promotion of macrophage efferocytosis for the treatment of IBD have been rare. We believe that this will be a new direction for IBD treatment. However, the specific mechanism of the efferocytosis process in IBD and the exploration of efferocytosis inducers need further study.

Autophagy affects the anti-inflammatory activity of macrophages Enhancing autophagy in intestinal macrophages is beneficial to the resolution of inflammation in IBD, while dysregulation of autophagy will lead to an intestinal macrophage-induced inflammatory cytokine storm and subsequent intestinal microbiota dysregulation [15]. In IBD patients, administration of the cannabinoid receptor 2 (CB2R) agonist cannabis reduces the severity of IBD by inducing autophagy and inhibiting macrophage-mediated inflammation [107]. Another study in patients showed

that targeting ATG2B to inhibit autophagy enhanced the secretion of proinflammatory cytokines by macrophages and adversely affected CD [108]. In a trinitrobenzenesulfonic acid-induced IBD mouse model, the well-known anti-inflammatory cytokine IL-33 ameliorated colitis by enhancing intestinal macrophage autophagy in the inflamed gut [109]. ATG16L1 knockout mice exhibited abnormal macrophage inflammasome activity in response to TLR and TNF stimulation [42].

Several studies have shown that autophagy can achieve inflammatory suppression by promoting the polarization of macrophages towards the M2 phenotype. The activation of PI3K/Akt, an important autophagy signaling pathway, is beneficial to the differentiation of M2 macrophages and the subsequent anti-inflammatory response [110]. The use of anti-TNF antibodies [40] or induction of AMP-activated protein kinase activation [111] both achieved an increase in the proportion of M2 macrophages, resulting in an anti-inflammatory effect. In turn, loss of autophagy in macrophages promotes inflammation by increasing M1 and reducing M2 polarization [40,43]. The altered phenotype will lead to dramatic differences in the cytokines secreted by macrophages, leading to the activation of different downstream inflammation-related signaling pathways. A recent study by Gao *et al.* [41], using ATG16L1 T300A polymorphism human macrophages and Atg16L1 T300A/T300A KI mouse cells showed that autophagy impairment caused by ATG16L1 T300A polymorphism leads to increased risk of CD by inducing the canonical NF- κ B-mediated inflammatory pathway. Transcriptome analysis revealed that the gene encoding the selective autophagy receptor optineurin in macrophages has reduced expression in ~10% of CD patients [46]. Deletion of optineurin leads to mistransportation of cytokines such as TNF and IL6 to lysosomes, thereby reducing serum TNF levels and making mice more susceptible to *Citrobacter rodentium*-induced colitis [47]. Promotion of autophagy in macrophages inhibits CD susceptibility gene protein tyrosine phosphatase non-receptor type 2 (PTPN2)-mediated initiation and activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, which triggers the maturation of pro-inflammatory cytokines such as IL-1 β and IL-18 thereby inhibiting colitis [112,113]. Conversely, the IBD-related risk gene myotubulin-related protein 3 increases PRR-induced IL-1 β secretion and NF- κ B activation by reducing autophagy in macrophages [48].

In addition to inflammatory factors, the production of ROS is also a key factor for tissue inflammation. Impaired autophagy, especially impaired mitophagy, increases ROS production, leading to tissue oxidative stress damage. Studies have shown that after LPS stimulation, human [43] or mouse [42] macrophages expressing dysfunctional ATG16L1 have impaired mitophagy, producing higher amounts of ROS and proinflammatory cytokines, impairing the processing of MHC class II antigens, altering intracellular trafficking to the lysosomal compartment and finally leading to colitis. Furthermore, macrophages depleted of LC3B,

exhibited dysfunctional mitochondria associated with increased ROS production, resulting in enhanced IL1 β and IL18 secretion in response to LPS [114]. Deficiency of the autophagy key gene ATG5 promotes macrophage secretion of the pro-inflammatory cytokine macrophage migration inhibitory factor, which basally responds to bacterial LPS in a mitochondrial ROS-dependent manner [49]. The macrophage-specific vacuolar-type ATPase (V-ATPase) subunit ATP6V0D2 significantly reduced the severity of DSS-induced colitis in mice by limiting inflammasome activation in macrophages and bacterial infection by pathogenic *S. typhimurium*, which was facilitated by enhanced levels of autophagosome-lysosome fusion and autophagic flux [50]. On the other hand, deficiency of the important anti-inflammatory factor IL-10, showed impaired mitophagy as well as impaired mitochondrial accumulation, increased ROS production and abnormal inflammasome activation after LPS stimulation *in vivo* and *in vitro* [115]. The IBD-related genes innate immunity activator (INAVA) [116] and autocrine/paracrine TNFSF15 [117] also affect the development of IBD by regulating ROS and autophagy pathways.

Autophagy is required in Wnt secretion and mucosal barrier integrity Wnt is a secreted, lipid-modified glycoprotein. Under physiological conditions, Wnt signaling is fundamental for maintaining intestinal epithelial homeostasis and renewal. Modulation of Wnt signaling contributes to histological improvement and mucosal healing in IBD patients [118]. WNT signaling has been identified as an upstream regulator of mammalian target of rapamycin (mTOR) signaling, promoting mTORC1 activity by preventing induction of the tuberous sclerosis complex [119]. The expression of Wnt1, one of the Wnt ligands, is increased in macrophages in the damaged mucosal lamina propria, and acts on epithelial cells in a paracrine manner to activate the Wnt pathway and mediate autophagy in epithelial cells, promoting mucosal repair of damaged tissues [77].

At present, in IBD, the research about Wnt mainly focuses on fibroblasts and epithelial cells, while the relationship with macrophages is insufficiently studied. However, we can see some possible common mechanisms in other examples of inflammatory diseases. Through the study of periodontal regeneration, it has been shown that Wnt/ β -catenin signaling activation can activate macrophage autophagy to promote the transformation to M2 type macrophages and achieve tissue repair [120]. Negative regulation of Wnt signaling by autophagy promotes the differentiation of Bone-marrow-derived macrophage (BMDM) into osteoclasts, thereby affecting tissue regeneration [121]. Wnt5A, a secreted Wnt glycoprotein ligand, is involved in tissue and organ morphogenesis. Wnt5A maintains cellular immune homeostasis by mediating the Rac1-NF- κ B pathway [122], and initiates efferocytosis to inhibit the spread of the pathogens *Pseudomonas aeruginosa* and *Streptococcus pneumoniae* [123]. IL-36 γ , a member of the IL-1 superfamily, regulates

autolysosome formation through non-canonical WNT signaling and the COX-2/AKT/mTOR pathway, contributing to WNT5A inhibition of intracellular *M. tuberculosis* growth [124].

In conclusion, the Wnt pathway in stimulated macrophages is related to its function in promoting tissue repair, and autophagy can regulate this activation to a certain extent. In addition, Wnt1 secreted by macrophages is beneficial for mucosal repair in epithelial cells. In-depth study of the relationship between autophagy and the Wnt pathway in macrophages will help to clarify the role of macrophages in mucosal repair.

Clinical application of macrophage autophagy-regulating drugs in the treatment of IBD

At present, there is no approved drug to treat IBD by targeting autophagy in macrophages. However, some clinically used drugs for IBD therapy have been shown to exert mechanisms related to autophagy regulation. Anti-TNF antibodies, such as infliximab, adalimumab and golimumab, are an important therapy in IBD biological treatment [125]. Anti-TNF antibodies can induce regulatory macrophages to a phenotype similar to M2, which participate in the suppression of inflammation. The autophagy levels are closely related to phenotypic changes, where ATG16L1 and autophagy-related protein cathepsin S play a key role [40]. Prins *et al.* [126] showed that the expression level of triggering receptor expressed on myeloid cells 1 (TREM-1) in CD14⁺ monocytes correlates with decreased autophagy and Fc-gamma receptors (FcγR) activity, resulting in a reduced rate of differentiation into M2-type macrophages following anti-TNF monoclonal antibody (mAb) treatment, which may explain the unresponsiveness to anti-TNF therapy of IBD patients with high levels of TREM-1 expression. The combination of autophagy agonist with anti-TNF mAb may benefit the response of IBD patients to this drug.

Therapies involving modulation of autophagy and the NLRP3 inflammasome to alleviate IBD have been extensively studied. Administration of andrographolide to mice with DSS-induced colitis enhanced mitophagy in peritoneal macrophages, thereby inhibiting the NLRP3 inflammasome and subsequently ameliorating colitis [127]. Agonist-mediated activation of cannabinoid receptor 2, a G protein-coupled receptor primarily located on immune cells, that inhibits NLRP3 inflammasome activation and alleviates DSS-induced colitis in mice by increasing autophagy, has been used in clinical treatment of IBD [128].

However, the use of autophagy modulators as an IBD therapy remains challenging given the low pharmacological specificity of these drug targets, lack of specificity for cell types and autophagy-independent effects.

Discussion

Atg16L1-, NRB2- and ATF4-deficient or mutant mice and humans have an increased chance of developing IBD, illustrating the importance of basal autophagy in maintaining

intestinal homeostasis and the intestinal defense barrier. However, hyperactivation of autophagy may aggravate IBD by inducing cell death, leading to gut barrier disruption and overproduction of proinflammatory cytokines [129–132]. Through patient samples, IBD mouse models and *in vitro* experiments, two recent studies [22,133] demonstrated that autophagy is closely related to corticotropin-releasing hormone-induced IBD, and blockade of autophagy in macrophages by chloroquine abrogates the adverse effects of corticotropin-releasing hormone. The possible reason why inhibition of autophagy is beneficial for IBD remission is that autophagy plays different roles in different disease processes. As a protective mechanism, autophagy may promote an anti-inflammatory response during the stage of inflammation, but excessive autophagy may lead to cell death under specific conditions [134]. Therefore, achieving the appropriate degree of macrophage autophagy is an important part of the treatment.

On the other hand, autophagy in different cells in the gut may have different effects on IBD development. Overall, current research suggests that autophagy by intestinal macrophages facilitates the phagocytosis of exogenous pathogenic bacteria and apoptotic cells, and promotes the repair of intestinal epithelial mucosal tissue. Increased susceptibility to IBD and loss of the mucosal barrier composed of intestinal epithelial cells have been observed in animal models with abnormal autophagy and in people with autophagy gene mutations [135]. However, autophagy in intestinal epithelial cells does not always help the body recover from IBD [136]. For example, the autophagy inhibitor chloroquine reduced the autophagic cell death of epithelial cells and attenuated the excessive inflammation it brings in a DSS-induced IBD mouse model deficient in ERBIN, which is an intestinal epithelial cell polarity-related protein [132]. Therefore, more in-depth studies are needed to distinguish the effect of cell-type-specific autophagy loss or activation on IBD outcome in different gut constituents. Drug delivery systems that precisely target and promote autophagy in intestinal macrophages may help improve the stability of drug therapy and reduce side effects.

In addition, under controlled conditions, M1 macrophages are beneficial for the destruction of exogenous pathogens, but excessive M1 activation can also produce a large number of toxic mediators to aggravate inflammation; however, M2 macrophages can balance these defects and promote tissue repair. Therefore, regulating the balance of macrophage subtypes is one of the important considerations in the treatment of IBD.

Conclusions

It has been suggested that promoting inflammation remission and damaged tissue repair is the aim of IBD treatment and an effective way to improve the life quality of IBD patients. Growing evidence has shown a close link between macrophage autophagy and IBD in animal models and

patients. In addition, recent studies have made remarkable discoveries regarding the key role of macrophage autophagy for IBD therapy: promoting pathogen and apoptotic cell clearance; activating anti-inflammatory activity; promoting tissue repair and barrier integrity. These findings open up new directions for therapeutic intervention in IBD. The next challenge in this field is how to target and controllably activate autophagy in macrophages and harness the benefits of this process for IBD therapy.

Abbreviations

AIEC: Adherent-invasive *Escherichia coli*; Akt: Protein kinase B; ATG: Autophagy-related genes; BMDM: Bone-marrow-derived macrophage; CD: Crohn's disease; DSS: Dextran sulfate sodium salt; FcγR: Fc-gamma receptors; GWAS: genome-wide association studies; IBD: Inflammatory bowel disease; IRGM: immunity-related GTPase family M protein; IL: Interleukin; INAVA: Innate immunity activator; LPS: Lipopolysaccharide; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NLR: NOD-like receptor; NLRP3: NOD-like receptor family pyrin domain containing 3; NOD2: Nucleotide-binding oligomerization domain 2; NPC: Niemann-Pick type C; NRBF2: Nuclear receptor binding factor 2; mAb: monoclonal antibody; mTOR: Mammalian target of rapamycin; RIPK2: Receptor interacting protein kinases 2; RNF186: Ring finger protein 186; PI3K: Phosphoinositide 3-kinases; PRR: Pattern recognition receptor; ROS: Reactive oxygen species; TLR: Toll-like receptor; TNF: Tumor necrosis factor; TREM-1: Triggering receptor expressed on myeloid cells 1; UC: Ulcerative colitis; V-ATPase: Vacuolar-type ATPase; XIAP: X-linked inhibitor of apoptosis protein.

Funding

This study was supported by the Shenzhen Fundamental Research Program (No. SGD20210823103804030), Science and Technology Development Fund, Macau SAR (No. 0025/2022/A1), the 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) (No. 2020B1212030006), Guangdong Basic and Applied Basic Research Foundation (No. 2022A1515012416), National Natural Science Foundation of China (No. 31871024) and the University of Macau grants (No. MYRG2019-00129-ICMS) awarded to JHL.

Author contribution

JHL and MYW designed the idea and framework of the review; EJW collected data and wrote the original manuscript; JHL, ZYR, YZ, RDY, CSHT and YTW participated in the review and revision of the original manuscript.

Conflicts of interest

The authors declare no competing interests.

Data availability

The datasets used in the present study are available from the first author and corresponding authors on reasonable request.

References

1. Carrière J, Darfeuille-Michaud A, Nguyen HTT. Infectious etiopathogenesis of Crohn's disease. *World J Gastroenterol* WJG. 2014;20:12102.
2. M'koma AE. Inflammatory bowel disease: an expanding global health problem. *Clin Med Insights Gastroenterol* SAGE Publications Sage UK: London, England. 2013;6:CGast-S12731.
3. Uhlig HH, Charbit-Henrion F, Kotlarz D, Shouval DS, Schwerdt T, Strisciuglio C, *et al.* Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the paediatric IBD Porto Group of European Society of paediatric gastroenterology, Hepatology and nutrition. *J Pediatr Gastroenterol Nutr.* 2021;72:456.
4. Cushing K, Higgins PDR. Management of Crohn disease: a review. *JAMA.* 2021;325:69–80.
5. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, *et al.* Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. *Ann Rheum Dis;* 2021;80:71–87.
6. Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. *World J Gastroenterol.* 2016;22:895.
7. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, *et al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature.* 2019;569:655–62.
8. Bushman FD, Conrad M, Ren Y, Zhao C, Gu C, Petucci C, *et al.* Multi-omic analysis of the interaction between Clostridioides difficile infection and pediatric inflammatory bowel disease. *Cell Host Microbe.* 2020;28:422–33.
9. Ryan FJ, Ahern AM, Fitzgerald RS, Laserna-Mendieta EJ, Power EM, Clooney AG, *et al.* Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat Commun.* 2020;11:1–12.
10. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature.* 2011;474:298–306.
11. Liu T-C, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. *Annu Rev Pathol Mech Dis.* 2016;11:127–48.
12. Nguyen HTT, Lapaquette P, Bringer M-A, Darfeuille-Michaud A. Autophagy and Crohn's disease. *Journal of Innate Immunity.* 2013;5:434–43.
13. Wu MY, Liu L, Wang EJ, Xiao HT, Cai CZ, Wang J, *et al.* PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. *Autophagy [Internet].* 2020;0:1 Available from: <https://doi.org/10.1080/15548627.2020.1741332>.
14. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, *et al.* A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet.* 2007;39:207–11.
15. Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. *Autophagy.* 2020;16:38–51.

16. Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. *Eur J Pharmacol.* 2020;877:173090.
17. Bain CC, Bravo-Blas A, Scott CL, Perdiguero EG, Geissmann F, Henri S, *et al.* Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat Immunol.* 2014;15:929–37.
18. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. *Nat Rev Immunol.* 2014;14:667–85.
19. Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol.* 2009;9:799–809.
20. Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, Greter M, *et al.* Origin of the lamina propria dendritic cell network. *Immunity.* 2009;31:513–25.
21. Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, *et al.* Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. *Mucosal Immunol.* 2013;6:498–510.
22. Wang S-L, Shao B-Z, Zhao S-B, Chang X, Wang P, Miao C-Y, *et al.* Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease. *Cell Death Dis.* 2019;10:1–17.
23. Lee H-Y, Kim J, Quan W, Lee J-C, Kim M-S, Kim S-H, *et al.* Autophagy deficiency in myeloid cells increases susceptibility to obesity-induced diabetes and experimental colitis. *Autophagy.* 2016;12:13390–1430.
24. Zhao S, Xia J, Wu X, Zhang L, Wang P, Wang H, *et al.* Deficiency in class III PI3-kinase confers postnatal lethality with IBD-like features in zebrafish. *Nat Commun.* 2018;9:1–13.
25. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology.* 2011;140:1704–12.
26. Ek WE, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. *Ann Gastroenterol Q Publ Hell Soc Gastroenterol. the Hellenic society of.* *Gastroenterology.* 2014;27:294.
27. Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, *et al.* Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology.* 2012;142:46–54.
28. Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cézard J-P, Belaiche J, *et al.* Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature.* 2001;411:599–603.
29. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, *et al.* A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature.* 2001;411:603–6.
30. Gammoh N. The multifaceted functions of ATG16L1 in autophagy and related processes. *J Cell Sci.* 2020;133: jcs249227.
31. Murthy A, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, *et al.* A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. *Nature.* 2014;506:456–62.
32. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, *et al.* Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet.* 2007;39:830–2.
33. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature.* 2011;469:323–35.
34. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science.* 2006;313:1438–41.
35. Saxena A, Lopes F, Poon KKH, McKay DM. Absence of the NOD2 protein renders epithelia more susceptible to barrier dysfunction due to mitochondrial dysfunction. *Am J Physiol Liver Physiol.* 2017;313:G26–38.
36. Lassen KG, McKenzie CI, Mari M, Murano T, Begun J, Baxt LA, *et al.* Genetic coding variant in GPR65 alters lysosomal pH and links lysosomal dysfunction with colitis risk. *Immunity.* 2016;44:1392–405.
37. Zhang HZ, Cui ZH, Cheng D, Du YY, Guo XL, Gao R, *et al.* RNF186 regulates EFN186 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis. *AutophagyHuazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Key Lab Mol Biophys, Minist Educ, 1037th Luoyu Ave, Wuhan 430074, Peoples R China.* 2021;17:3030–47.
38. Ranjan K, Hedl M, Abraham C. The E3 ubiquitin ligase RNF186 and RNF186 risk variants regulate innate receptor-induced outcomes. *Proc Natl Acad Sci.* 2021;118: e2013500118.
39. Homer CR, Richmond AL, Rebert NA, Achkar J, McDonald C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. *Gastroenterology.* 2010;139:1630–41.
40. Levin AD, Koelink PJ, Bloemendaal FM, Vos ACW, D'Haens GR, van den Brink GR, *et al.* Autophagy contributes to the induction of anti-TNF induced macrophages. *J Crohn's Colitis.* 2016;10:323–9.
41. Gao P, Liu H, Huang H, Sun Y, Jia B, Hou B, *et al.* The Crohn disease-associated ATG16L1T300A polymorphism regulates inflammatory responses by modulating TLR-and NLR-mediated signaling. *Autophagy.* 2022;18:2561–75.
42. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang B-G, Satoh T, *et al.* Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1 β production. *Nature.* 2008;456: 264–8.
43. Zhang H, Zheng L, McGovern DPB, Hamill AM, Ichikawa R, Kanazawa Y, *et al.* Myeloid ATG16L1 facilitates host–bacteria interactions in maintaining intestinal homeostasis. *J Immunol.* 2017;198:2133–46.
44. Buisson A, Douadi C, Ouchchane L, Goutte M, Hugot J-P, Dubois A, *et al.* Macrophages inability to mediate adherent-invasive E. coli replication is linked to autophagy in Crohn's disease patients. *Cell.* 2019;8:1394.
45. Schwerdt T, Pandey S, Yang H-T, Bagola K, Jameson E, Jung J, *et al.* Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. *Gut.* 2017;66:1060–73.
46. Smith AM, Sewell GW, Levine AP, Chew TS, Dunne J, O'Shea NR, *et al.* Disruption of macrophage pro-inflammatory cytokine release in Crohn's disease is associated with reduced optineurin expression in a subset of patients. *Immunology.* 2015;144:45–55.
47. Chew TS, O'Shea NR, Sewell GW, Oehlers SH, Mulvey CM, Crosier PS, *et al.* Optineurin deficiency in mice contributes to impaired cytokine secretion and neutrophil recruitment in bacteria-driven colitis. *Dis Model Mech.* 2015;8:817–29.
48. Lahiri A, Hedl M, Abraham C. MTMR3 risk allele enhances innate receptor-induced signaling and cytokines by decreasing autophagy and increasing caspase-1 activation. *Proc Natl Acad Sci.* 2015;112:10461–6.

49. Lee JPW, Foote A, Fan H, Peral de Castro C, Lang T, Jones SA, *et al.* Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. *Autophagy*. 2016;12:907–16.
50. Xia Y, Liu N, Xie X, Bi G, Ba H, Li L, *et al.* The macrophage-specific V-ATPase subunit ATP6V0D2 restricts inflammasome activation and bacterial infection by facilitating autophagosome-lysosome fusion. *Autophagy*. 2019;15: 960–75.
51. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. *Nat Rev Mol Cell Biol*. 2014;15:19–33.
52. Zheng Y, Yu Y, Chen X-F, Yang S-L, Tang X-L, Xiang Z-G. Intestinal macrophage autophagy and its pharmacological application in inflammatory bowel disease. *Front Pharmacol*. 2021;12:803686.
53. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort H. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. *Bull World Health Organ*. 1972;46:845.
54. Cummings RJ, Barbet G, Bongers G, Hartmann BM, Gettler K, Muniz L, *et al.* Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs. *Nature*. 2016;539:565–9.
55. Poon IKH, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. *Nat Rev Immunol*. 2014;14:166–80.
56. Qualls JE, Kaplan AM, Van Rooijen N, Cohen DA. Suppression of experimental colitis by intestinal mononuclear phagocytes. *J Leukoc Biol*. 2006;80:802–15.
57. Hume DA, Perry VH, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localisation of antigen F4/80: macrophages associated with epithelia. *Anat Rec*. 1984;210:503–12.
58. Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. *Immunol Rev*. 2014;260:102–17.
59. Seyedizade SS, Afshari K, Bayat S, Rahmani F, Momtaz S, Rezaei N, *et al.* Current status of M1 and M2 macrophages pathway as drug targets for inflammatory bowel disease. *Arch Immunol Ther Exp*. 2020;68:1–24.
60. Zhu W, Yu J, Nie Y, Shi X, Liu Y, Li F, *et al.* Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. *Immunol Investig*. 2014;43:638–52.
61. Köhl AA, Erben U, Kredel LI, Siegmund B. Diversity of intestinal macrophages in inflammatory bowel diseases. *Front Immunol*. 2015;6:613.
62. Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. *Expert Opin Ther Targets*. 2021;25:191–209.
63. Hidalgo-García L, Galvez J, Rodríguez-Cabezas ME, Anderson PO. Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine? *Front Pharmacol*. 2018;9:179.
64. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology*. 2011;140:1729–37.
65. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing $\gamma\delta$ T cells selectively expand in response to pathogen products and environmental signals. *Immunity*. 2009;31:321–30.
66. Zigmund E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, *et al.* Ly6Chi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. *Immunity*. 2012;37:1076–90.
67. Bosurgi L, Cao YG, Cabeza-Cabrero M, Tucci A, Hughes LD, Kong Y, *et al.* Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. *Science*. 2017;356:1072–6.
68. Lee C, Penberthy K, Wheeler K, Juncadella I, Vandenabeele P, Lysiak J, *et al.* Boosting apoptotic cell clearance by colonic epithelial cells attenuates inflammation in vivo. *Immunity*. 2016;S1074761316300206.
69. A-Gonzalez N, Quintana JA, García-Silva S, Mazariegos M, González de la Aleja A, Nicolás-Ávila JA, *et al.* Phagocytosis imprints heterogeneity in tissue-resident macrophages. *J Exp Med*. 2017;214:1281–96.
70. Noelia A, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, *et al.* Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. *Immunity*. 2009;31:245–58.
71. Lin S-L, Li B, Rao S, Yeo E-J, Hudson TE, Nowlin BT, *et al.* Macrophage Wnt7b is critical for kidney repair and regeneration. *Proc Natl Acad Sci*. 2010;107:4194–9.
72. Farin HF, Van Es JH, Clevers H. Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells. *Gastroenterology*. 2012;143:1518–29.
73. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. *Proc Natl Acad Sci*. 2005;102:99–104.
74. Anderson EC, Wong MH. Caught in the Akt: regulation of Wnt signaling in the intestine. *Gastroenterology*. 2010;139:718–22.
75. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. *Journal of Innate Immunity*. 2011;3:550–64.
76. D'Angelo F, Bernasconi E, Schäfer M, Moyat M, Michetti P, Maillard MH, *et al.* Macrophages promote epithelial repair through hepatocyte growth factor secretion. *Clin Exp Immunol*. 2013;174:60–72.
77. Ortiz-Masia D, Cosin-Roger J, Calatayud S, Hernandez C, Alos R, Hinojosa J, *et al.* Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: relevance in IBD. *Mucosal Immunol*. 2014;7:929–38.
78. Talero E, Garcia-Maurino S, Motilva V. Melatonin, autophagy and intestinal bowel disease. *Curr Pharm Des*. 2014;20: 4816–27.
79. Travassos LH, Carneiro LAM, Ramjeet M, Hussey S, Kim Y-G, Magalhães JG, *et al.* Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat Immunol*. 2010;11:55–62.
80. Lapaquette P, Glasser A, Huett A, Xavier RJ, Darfeuille-Michaud A. Crohn's disease-associated adherent-invasive *E. coli* are selectively favoured by impaired autophagy to replicate intracellularly. *Cell Microbiol*. 2010;12:99–113.
81. Strisciuglio C, Duijvestein M, Verhaar AP, Vos ACW, den Brink GR, Hommes DW, *et al.* Impaired autophagy leads to abnormal dendritic cell–epithelial cell interactions. *J Crohn's Colitis*. 2013;7:534–41.

82. Ogawa M, Yoshikawa Y, Kobayashi T, Mimuro H, Fukumatsu M, Kiga K, *et al.* A Tecpr1-dependent selective autophagy pathway targets bacterial pathogens. *Cell Host Microbe*. 2011;9:376–89.
83. Cemama M, Kim PK, Brumell JH. The ubiquitin-binding adaptor proteins p62/SQSTM1 and NDP52 are recruited independently to bacteria-associated microdomains to target salmonella to the autophagy pathway. *Autophagy*. 2011;7:341–5.
84. Randow F. How cells deploy ubiquitin and autophagy to defend their cytosol from bacterial invasion. *Autophagy*. 2011;7:304–9.
85. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, *et al.* Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut*. 2006;55:205–11.
86. Martinez-Medina M, Aldegue X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, *et al.* Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIEC) in Crohn's disease. *Inflamm Bowel Dis*. 2009;15:872–82.
87. Rolhion N, Darfeuille-Michaud A. Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Inflamm Bowel Dis*. 2007;13:1277–83.
88. Caprilli R, Lapaquette P, Darfeuille-Michaud A. Eating the enemy in Crohn's disease: an old theory revisited. *J Crohn's Colitis*. 2010;4:377–83.
89. Darfeuille-Michaud A. Adherent-invasive *Escherichia coli*: a putative new *E. coli* pathotype associated with Crohn's disease. *International Journal of Medical Microbiology*. 2002;292:185–93.
90. Glasser A-L, Boudeau J, Barnich N, Perruchot M-H, Colombel J-F, Darfeuille-Michaud A. Adherent invasive *Escherichia coli* strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. *Infect Immun*. 2001;69:5529–37.
91. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, *et al.* Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Gut*. 2018;67:574–87.
92. Sun R, Abraham C. IL23 promotes antimicrobial pathways in human macrophages, which are reduced with the IBD-protective IL23R R381Q variant. *Cellular and Molecular Gastroenterology and Hepatology*. 2020;10:673–97.
93. Shi C-S, Kehrl JH. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. *J Biol Chem*. 2008;283:33175–82.
94. Xu YI, Jagannath C, Liu X-D, Sharafkhaneh A, Kolodziejaska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. *Immunity*. 2007;27:135–44.
95. Krause K, Caution K, Badr A, Hamilton K, Saleh A, Patel K, *et al.* CASP4/caspase-11 promotes autophagosome formation in response to bacterial infection. *Autophagy*. 2018;14:1928–42.
96. Abdolmaleki F, Farahani N, Gheibi Hayat SM, Pirro M, Bianconi V, Barreto GE, *et al.* The role of efferocytosis in autoimmune diseases. *Front Immunol*. 2018;9:1645.
97. Morioka S, Maueröder C, Ravichandran KS. Living on the edge: Efferocytosis at the interface of homeostasis and pathology. *Immunity*. 2019;50:1149–62.
98. Angsana J, Chen J, Liu L, Haller CA, Chaikof EL. Efferocytosis as a regulator of macrophage chemokine receptor expression and polarization. *Eur J Immunol*. 2016;46:1592–9.
99. Mehrotra P, Ravichandran KS. Drugging the efferocytosis process: concepts and opportunities. *Nat Rev Drug Discov*. 2022;21:601–20.
100. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. *Nat Rev Rheumatol*. 2010;6:280–9.
101. Korns D, Frasch SC, Fernandez-Boyanapalli R, Henson PM, Bratton DL. Modulation of macrophage efferocytosis in inflammation. *Front Immunol*. 2011;2:57.
102. Martin-Rodriguez O, Gauthier T, Bonnefoy F, Couturier M, Daoui A, Chagué C, *et al.* Pro-resolving factors released by macrophages after Efferocytosis promote mucosal wound healing in inflammatory bowel disease. *Front Immunol*. 2021;12:754475.
103. Heckmann BL, Green DR. LC3-associated phagocytosis at a glance. *J Cell Sci*. 2019;132:0–2.
104. Liu B, Zhang B, Guo R, Li S, Xu Y. Enhancement in efferocytosis of oxidized low-density lipoprotein-induced apoptotic RAW264. 7 cells through Sirt1-mediated autophagy. *Int J Mol Med*. 2014;33:523–33.
105. Ouimet M, Ediriweera H, Afonso MS, Ramkhalawon B, Singaravelu R, Liao X, *et al.* microRNA-33 regulates macrophage autophagy in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2017;37:1058–67.
106. Wang Z, Sequeira RC, Zabalawi M, Madenspacher J, Boudyguina E, Ou T, *et al.* Myeloid atg5 deletion impairs n-3 PUFA-mediated atheroprotection. *Atherosclerosis*. 2020;295:8–17.
107. Tartakover Matalon S, Ringel Y, Konikoff F, Drucker L, Pery S, Naftali T. Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. *United Eur Gastroenterol J*. SAGE Publications Sage UK: London, England; 2020;8:271–83.
108. Lin X, Zheng X, Fan D, Yao Q, Hu J, Lian L, *et al.* MicroRNA-143 targets ATG2B to inhibit autophagy and increase inflammatory responses in Crohn's disease. *Inflamm Bowel Dis*. 2018;24:781–91.
109. Wang Z, Shi L, Hua S, Qi C, Fang M. IL-33 ameliorates experimental colitis involving regulation of autophagy of macrophages in mice. *Cell & Bioscience*. 2019;9:1–9.
110. López-Peláez M, Soria-Castro I, Bosca L, Fernández M, Alemany S. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression. *Eur J Immunol*. 2011;41:1733–41.
111. Liu R, Li X, Ma H, Yang Q, Shang Q, Song L, *et al.* Spermidine endows macrophages anti-inflammatory properties by inducing mitochondrial superoxide-dependent AMPK activation, Hif-1 α upregulation and autophagy. *Free Radic Biol Med*. 2020;161:339–50.
112. Chuang S-Y, Yang C-H, Chou C-C, Chiang Y-P, Chuang T-H, Hsu L-C. TLR-induced PAI-2 expression suppresses IL-1 β processing via increasing autophagy and NLRP3 degradation. *Proc Natl Acad Sci*. 2013;110:16079–84.
113. Spalinger MR, Lang S, Gottier C, Dai X, Rawlings DJ, Chan AC, *et al.* PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. *Autophagy*. 2017;13:1590–601.
114. Nakahira K, Haspel JA, Rathinam VAK, Lee S-J, Dolinay T, Lam HC, *et al.* Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial

- DNA mediated by the NALP3 inflammasome. *Nat Immunol.* 2011;12:222–30.
115. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. *Science.* 2017;356:513–9.
 116. Yan J, Hedl M, Abraham C. An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes. *J Clin Invest.* 2017;127:2192–205.
 117. Sun R, Hedl M, Abraham C. TNFSF15 promotes antimicrobial pathways in human macrophages and these are modulated by TNFSF15 disease-risk variants. *Cellular and Molecular Gastroenterology and Hepatology.* 2021;11:249–72.
 118. Moparthi L, Koch S. Wnt signaling in intestinal inflammation. *Differentiation.* 2019;108:24–32.
 119. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. *Nat Rev Mol Cell Biol.* 2014;15:155–62.
 120. Zheng X, Wang S, Xiao L, Han P, Xie K, Ivanovski S, *et al.* LiCl-induced immunomodulatory periodontal regeneration via the activation of the Wnt/ β -catenin signaling pathway. *J Periodontol Res.* 2022;57:835–48.
 121. Chen L, Yang Y, Bao J, Wang Z, Xia M, Dai A, *et al.* Autophagy negative-regulating Wnt signaling enhanced inflammatory osteoclastogenesis from pre-OCs in vitro. *Biomed Pharmacother.* 2020;126:110093.
 122. Naskar D, Maiti G, Chakraborty A, Roy A, Chattopadhyay D, Sen M. Wnt5a–Rac1–NF- κ B homeostatic circuitry sustains innate immune functions in macrophages. *J Immunol.* 2014;192:4386–97.
 123. Jati S, Kundu S, Chakraborty A, Mahata SK, Nizet V, Sen M. Wnt5A signaling promotes defense against bacterial pathogens by activating a host autophagy circuit. *Front Immunol.* 2018;9:679.
 124. Gao Y, Wen Q, Hu S, Zhou X, Xiong W, Du X, *et al.* IL-36 γ promotes killing of mycobacterium tuberculosis by macrophages via WNT5A-induced noncanonical WNT signaling. *J Immunol.* 2019;203:922–35.
 125. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johans J, *et al.* Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. *Gastroenterology.* 2014;146:96–109.
 126. Prins MM, Verstockt B, Ferrante M, Vermeire S, Wildenberg ME, Koelink PJ. Monocyte TREM-1 levels associate with anti-TNF responsiveness in IBD through autophagy and Fc γ -receptor Signaling pathways. *Front Immunol.* 2021;12: 627535.
 127. Guo W, Sun Y, Liu W, Wu X, Guo L, Cai P, *et al.* Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. *Autophagy.* 2014;10:972–85.
 128. Shao B, Wei W, Ke P, Xu Z, Zhou J, Liu C. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP 3 inflammasome. *CNS Neuroscience & Therapeutics.* 2014;20:1021–8.
 129. Thachil É, Hugot J, Arbeille B, Paris R, Grodet A, Peuchmaur M, *et al.* Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease. *Gastroenterology.* 2012;142:1097–9.
 130. Wlodarska M, Thaïss CA, Nowarski R, Henao-Mejia J, Zhang J-P, Brown EM, *et al.* NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. *Cell.* 2014;156:1045–59.
 131. Cosin-Roger J, Simmen S, Melhem H, Atrott K, Frey-Wagner I, Hausmann M, *et al.* Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun.* 2017;8:1–13.
 132. Shen T, Li S, Cai L-D, Liu J-L, Wang C-Y, Gan W-J, *et al.* Erbin exerts a protective effect against inflammatory bowel disease by suppressing autophagic cell death. *Oncotarget.* 2018;9:12035.
 133. Zhao S-B, Wu J-Y, He Z-X, Song Y-H, Chang X, Xia T, *et al.* Corticotropin releasing hormone promotes inflammatory bowel disease via inducing intestinal macrophage autophagy. *Cell death Discov.* 2021;7:1–13.
 134. Denton D, Kumar S. Autophagy-dependent cell death. *Cell Death Differ.* 2019;26:605–16.
 135. Baxt LA, Xavier RJ. Role of autophagy in the maintenance of intestinal homeostasis. *Gastroenterology.* 2015;149:553–62.
 136. Foerster EG, Mukherjee T, Cabral-Fernandes L, Rocha JDB, Girardin SE, Philpott DJ. How autophagy controls the intestinal epithelial barrier. *Autophagy.* 2022;18:86–103.